M. Kraus & Co’s Bristol-Myers Squibb BMY Stock Holding History

M. Kraus & Co’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-4,279	Closed	-$232K	–	81
2024 Q1	$232K	Sell	4,279 -240	-5%	-$12.2K	0.07%	74
2023 Q4	$232K	Sell	4,519 -559	-11%	-$29.3K	0.08%	74
2023 Q3	$295K	Sell	5,078 -350	-6%	-$21.4K	0.1%	62
2023 Q2	$347K	Sell	5,428 -1,208	-18%	-$81K	0.12%	57
2023 Q1	$460K	Buy	6,636 +9	+0.1%	+$635	0.16%	52
2022 Q4	$477K	Buy	6,627 +2,194	+49%	+$165K	0.18%	50
2022 Q3	$315K	Buy	4,433 +795	+22%	+$57.7K	0.13%	55
2022 Q2	$280K	Hold	3,638	–	–	0.11%	59
2022 Q1	$266K	Buy	+3,638	New	+$244K	0.09%	66
2016 Q3	–	Sell	-3,570	Closed	-$263K	–	51
2016 Q2	$263K	Hold	3,570	–	–	0.19%	45
2016 Q1	$228K	Hold	3,570	–	–	0.17%	47
2015 Q4	$246K	Buy	+3,570	New	+$236K	0.18%	47
2015 Q3	–	Sell	-3,370	Closed	-$224K	–	49
2015 Q2	$224K	Hold	3,370	–	–	0.16%	47
2015 Q1	$217K	Buy	+3,370	New	+$211K	0.16%	47

Other funds holding BMY

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

M. Kraus & Co's BMY Position: Q2 2024 in Review

M. Kraus & Co sold out of Bristol-Myers Squibb (BMY) in Q2 2024, closing a stake of 4,279 shares — an estimated $232K sold.

M. Kraus & Co first reported a position in BMY in Q1 2015 and held it in 14 quarters. The position peaked at $477K in Q4 2022. 2,147 funds tracked by Wall St. Rank hold BMY as of Q2 2024.

M. Kraus & Co reported no remaining Bristol-Myers Squibb position as of Q2 2024 after selling out during the quarter.
M. Kraus & Co sold 4,279 Bristol-Myers Squibb shares in Q2 2024, an estimated $232K.
M. Kraus & Co first reported a position in Bristol-Myers Squibb in Q1 2015 and held it in 14 quarters.
M. Kraus & Co's Bristol-Myers Squibb position peaked at $477K in Q4 2022.
2,147 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2024.

Based on M. Kraus & Co's 13F filing for Q2 2024, filed 10 Jul 2024.